Jon Congleton, Mineralys

Min­eralys emerges with a new take on an old idea for the treat­ment of hy­per­ten­sion and $40M to play with

Al­dos­terone, a hor­mone linked to in­creased blood pres­sure, has long been a tar­get of in­ter­est for the treat­ment of hy­per­ten­sion, but se­lec­tiv­i­ty has been a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA